Melanomagenesis is frequently driven by mutations in BRAF or NRAS oncogenes that lead to constitutive activation of MAPK cascade, eventually inducing both Fra-1 and Fra-2 expression in malignant melanoma (MM) cells [18, 67]. The gene discussed is FOSL2; the disease is Miyoshi myopathy.